When does Reyvow (lasmiditan) lose patent exclusivity?
DrugPatentWatch does track patent and exclusivity timelines for Reyvow (lasmiditan), which can be the fastest way to find the most relevant “expiry date” information for the specific filings tied to the product. Check the Reyvow page on DrugPatentWatch for the current estimated/claimed patent-expiration dates and any relevant exclusivity milestones: DrugPatentWatch – Reyvow. [1]
Which “expiry date” do you mean for Reyvow?
People searching “Reyvow expiry date” usually mean one of these:
- Patent expiry for the active ingredient or key formulation/use patents (the typical trigger for generic entry, though it depends on the remaining legal landscape).
- Regulatory exclusivity (data exclusivity/exclusivity periods granted under drug law), which can delay approvals even if a patent is no longer listed.
- Market exclusivity tied to specific regulatory events.
DrugPatentWatch is helpful because it links the product to the specific patent estate and shows the dates tied to those assets. [1]
Can generics or other competitors enter before every listed date?
Even if a listed patent date has passed, entry can still be delayed by:
- Other still-active patents covering related claims (for example, a different formulation, dosing method, or use).
- Litigation or “orange book” type barriers (where relevant).
- Remaining regulatory exclusivity.
Those scenarios are also reflected in how patent date lists are interpreted, so it’s important to use the DrugPatentWatch dates as a starting point and confirm which patents are still driving exclusivity for the product. [1]
What’s the quickest way to get the exact date you need?
If you tell me which country you care about (U.S., EU, UK, etc.) and whether you mean “patent expiry” or “regulatory exclusivity,” I can narrow down which date to look for on the DrugPatentWatch record. [1]
Sources:
1. https://www.drugpatentwatch.com/